Clinical Trials Browser

INDUSTRY × Carcinoma, Transitional Cell × 30 days × Clear all

NCT03967977 2026-04-17

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

Phase 3 Active not recruiting

420 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT05861947 2026-04-17

JIVAN

Phase 1 Terminated

21 enrolled

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Colonic Neoplasms, Esophageal Neoplasms, Kidney Neoplasms, Recurrence, Stomach Neoplasms

NCT07218380 2026-04-17

FORAGER-2

Phase 3 Recruiting

450 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT07416123 2026-04-16

A Study of GEN1106 in Participants With Solid Tumors

Phase 1 Recruiting

103 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT05581004 2026-04-15

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1 Recruiting

450 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms

NCT07518043 2026-04-15

A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors

Phase 1 Not yet recruiting

174 enrolled

DermatologicGenitourinary

Carcinoma, Transitional Cell, Melanoma

NCT06443944 2026-04-14

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Available

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT04895709 2026-04-13

A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

949 enrolled

BreastDermatologicGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Melanoma, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT06582017 2026-04-13

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

Phase 1 Recruiting

100 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT07526792 2026-04-13

SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Phase 3 Not yet recruiting

406 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT06695845 2026-04-09

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Phase 2 Recruiting

200 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05911295 2026-04-07

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

Phase 3 Active not recruiting

412 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07090499 2026-04-07

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

Phase 1 Recruiting

310 enrolled

GastrointestinalGenitourinaryHead & NeckThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Head and Neck Neoplasms, Pancreatic Neoplasms

NCT07421700 2026-04-07

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

Phase 1/2 Recruiting

132 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07484022 2026-04-07

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Phase 1 Recruiting

37 enrolled

Genitourinary

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

NCT07277413 2026-04-03

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Phase 1 Recruiting

260 enrolled

GastrointestinalGenitourinaryOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Mesothelioma, Neoplasm Metastasis, Recurrence

NCT04822350 2026-04-02

AVENANCE

Completed

596 enrolled 43 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05562830 2026-04-02

MK-3475-04A

Phase 1/2 Active not recruiting

48 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT06451497 2026-04-02

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Phase 1 Recruiting

100 enrolled

BreastGastrointestinalGenitourinaryHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Triple Negative Breast Neoplasms

NCT07287995 2026-04-01

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Phase 1/2 Recruiting

428 enrolled

BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT02138734 2026-03-31

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Phase 1/2 Active not recruiting

369 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms

NCT03815643 2026-03-31

Avelumab Program Rollover Study

Phase 3 Active not recruiting

205 enrolled

GenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Ovarian Neoplasms

NCT03473743 2026-03-30

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

Phase 1/2 Active not recruiting

125 enrolled 19 charts

Genitourinary

Carcinoma, Transitional Cell

NCT07492628 2026-03-25

DUET-UC-NK

Phase 1 Recruiting

42 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT03288545 2026-03-24

EV-103

Phase 1/2 Terminated

348 enrolled 2 FDA

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT06293898 2026-03-23

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Phase 1 Recruiting

280 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT05661955 2026-03-20